Navigation Links
Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
Date:11/16/2010

rganic Anion Transporter 1 (hOAT1) and hOAT3, which are both linked to kidney excretion of endogenous substances and certain drugs.  Researchers noted that net uptake of CMX001 and CMX157 was not enhanced in OAT-expressing cells.  These data provide evidence that CMX001 and CMX157 are not substrates of human OAT1 and OAT3 and therefore have a low potential to cause OAT-mediated nephrotoxicity.  In contrast, uptake of cidofovir and tenofovir was enhanced in in vitro cells expressing OAT1, consistent with previous literature reports.  

"Nephrotoxicity is a serious and potentially life-threatening adverse effect associated with the antiviral agents cidofovir and tenofovir.  Through the application of our proprietary PIM Conjugate Technology we are able to dramatically alter drug distribution and thereby potentially avoid nephrotoxicity," said George Painter, Ph.D., Chief Scientific Officer of Chimerix.  "Our animal and clinical studies of CMX001 and CMX157, in which both compounds have demonstrated a positive safety profile, are consistent with our in vitro observations that CMX001 and CMX157 are not metabolized in the kidney.  Furthermore, these data are consistent with, and provide a mechanistic explanation for, data presented at the recent ICAAC meeting that CMX001 was well tolerated in 46 patients with compromised renal function."

Chimerix is developing CMX001 for dual-use as a broad-spectrum antiviral for the treatment of life-threatening viruses in immunocompromised transplant and cancer patients and as a medical countermeasure in the event of a smallpox release.  CMX001 is currently in Phase 2 clinical trials for the prophylaxis and treatment of human cytomegalovirus infection. CMX157 is currently in Phase 1 clinical testing for the treatment of HIV infections.

Cidofovir and tenofovir are polar, acyclic nucleoside phosphonates that are FDA-approved as Vistide® (cidofovir injection) f
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
5. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
6. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
7. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
8. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
9. New forms of highly efficient, flexible nanogenerator technology
10. Verenium to Present at Jefferies 10th Global Clean Technology Conference
11. Voluntary initiatives, regulation and nanotechnology oversight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Connecticut Center ... organization based in East Hartford, Conn., was awarded a ... II of a project that will determine the feasibility ... rural north-central Connecticut. USDA Rural Development provided $53,000 for ... for the second phase of the feasibility study in ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing ... round of seed financing from friends and family investors. ... develop a novel sustained-release product for ophthalmology. , "We ... their commitment to this important work," said Dr. Ken ... of many areas in which innovations in drug delivery ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... 25 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. (OTC ... a leading provider in the nutraceutical industry ... organic nutritional food,products, supplements, and personal care ... today announced that it has formally completed ...
... Calif., April 25 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... 2008., For the quarter ended March 31, 2008, the ... share. This compares to a net loss of $34.1,million, or ... 2007,and $55.1 million, or $0.93 per share, for the same ...
... Biologists call for making available more detailed maps of the ... biotech crops on a county and township level will give ... on wildlife, water quality, and on pest and beneficial insects. ... have been planted with biotech crops in the U.S.," said ...
Cached Biology Technology:China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 2China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 3CV Therapeutics Reports 2008 First Quarter Financial Results 2CV Therapeutics Reports 2008 First Quarter Financial Results 3CV Therapeutics Reports 2008 First Quarter Financial Results 4CV Therapeutics Reports 2008 First Quarter Financial Results 5Scientists call for more access to biotech crop data 2
(Date:7/30/2014)... Queen in Lewis Carroll,s Through the Looking Glass, ... University of Singapore improved a 35-year-old ecology model ... to millions of years. , The new model, ... the "Red Queen Effect," an evolutionary hypothesis introduced ... suggests that organisms must constantly increase their fitness ...
(Date:7/30/2014)... of climate change on the world,s animal and ... according to a new paper by a research ... Queensland, and other organizations. The authors claim that ... point when it comes to climate change. ... focus on the "direct" threats of changing temperatures ...
(Date:7/30/2014)... researchers from the University of Helsinki and the Universitat ... in mice morphological changes which have taken millions of ... the embryonic development of mice teeth, induced in the ... similar to those observed in the fossil registry of ... ago. , To modify the development of their ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Conservation scientists asking wrong questions on climate change impacts on wildlife 2Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2
... Recognizing faces is an important social skill, but not all ... unable to recognize even their closest friends (a condition called ... of faces. Now a twin study by collaborators at MIT ... and that it is inherited separately from general intelligence or ...
... observer in the Gulf of Mexico, the seemingly sluggish red ... beaver. But a new study led by researchers at The ... and ecosystem engineer. Most abundant along Florida,s west coast ... caverns from North Carolina to Brazil, the red grouper excavates ...
... City, Mexico and Cambridge, MA, USA Tuesday, January 19 ... of a major research project in genomic medicine that will ... the world. The project will be carried out by ... Broad Institute of MIT and Harvard and the National Institute ...
Cached Biology News:Face recognition ability inherited separately from IQ 2Face recognition ability inherited separately from IQ 3New study reveals red grouper to be 'Frank Lloyd Wrights of the sea' 2New study reveals red grouper to be 'Frank Lloyd Wrights of the sea' 3Mexico-US collaboration launched to study major human diseases 2
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Digest Medium (TSB), USP is a highly ... general laboratory use. Due to the inclusion ... medium will support growth of many fastidious ... , Product conforms to United States Pharmacopeia ...
... and endothelial cells-directed transfection reagent ... peptide-conjugated polyethylenimine which allows targeted ... and endothelial cells. Integrins are ... and cell-matrix adhesion processes. Many ...
... is used to predict the ... sequence up to 3,200 bases, ... of primers and GC clamps ... gradient gel electrophoresis (DGGE), constant ...
Biology Products: